Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Phase 3 trialsStub

SS-31

Mitochondria-targeted tetrapeptide (elamipretide)

A four amino acid peptide that binds cardiolipin in the inner mitochondrial membrane. As elamipretide it has been through phase 3 trials and regulatory review for Barth syndrome.

Reconstitution calculator

At a glance

Phase 3 trials

Large randomized trials in people are running or published. It is not a licensed medicine.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3: SS-31

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

454
papers on PubMed
197
of them in people
18
randomized trials
94
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on SS-31 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of SS-31; no amount here is a recommendation.

SS-31: on PubMed

What PubMed held for SS-31 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

454
papers
197
in humans
20
clinical trials
18
randomized trials
2012: 3 papers122013: 6 papers2014: 13 papers142015: 15 papers2016: 15 papers162017: 24 papers2018: 30 papers182019: 30 papers2020: 30 papers202021: 40 papers2022: 40 papers222023: 32 papers2024: 59 papers242025: 72 papers2026: 76 papers so far26
Papers per year, 2012 to 2026. The most in one year: 76.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

    Randomized trialKaraa A, Bertini E, Carelli V, et al. Neurology, 2023. PMID 37268435

  2. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER

    Randomized trialThompson WR, Manuel R, Abbruscato A, et al. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181

  3. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Randomized trialSherrod CF 4th, Saberi S, Nassif ME, et al. Journal of the American College of Cardiology, 2024. PMID 39217569

  4. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial

    Randomized trialKaraa A, Bertini E, Carelli V, et al. Orphanet journal of rare diseases, 2024. PMID 39574155

  5. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data

    Randomized trialVan den Eynde J, Chinni B, Vernon H, et al. Orphanet journal of rare diseases, 2023. PMID 37041653

  6. The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction

    Randomized trialHortmann M, Robinson S, Mohr M, et al. European heart journal. Acute cardiovascular care, 2019. PMID 28534645

  7. Elamipretide Hydrochloride

    StudyAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026. PMID 41206662

  8. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice

    StudyZhao W, Xu Z, Cao J, et al. Journal of neuroinflammation, 2019. PMID 31747905

Search used: (elamipretide[tiab] OR "SS-31"[tiab] OR "MTP-131"[tiab]). Run it on PubMed

Research links

Also in Skin and longevity